DPC-423 Bristol-Myers Squibb.
DPC-423 is a biphenylamine-containing amide which is under development by Bristol-Myers Squibb (formerly DuPont Pharmaceuticals) as a Factor Xa inhibitor for the potential treatment of thrombotic disorders [372092]. As of August 2000, DPC-423 was in phase I trials [380880]. DPC-423 was discovered as a result of SAR modifications of DuPont's SN-429, including replacement of the benzamidine moiety with a less basic benzylamine [398701]. Its 2-aminomethylphenyl analog DPC-602 is also under investigation for thrombotic disorders [402714].